Dr. Vijayvergia discussed key findings from the CABINET trial comparing cabozantinib to placebo in patients with advanced GI neuroendocrine tumors. She further discussed the impact of these findings on the treatment landscape for patients with pancreatic and extra pancreatic neuroendocrine tumors, followed by how cabozantinib can be integrated into clinical practice, considering factors like tumor grade, functional status, and prior therapies.